Influence of CYP2C9 genotype on warfarin dose among African-Americans and European-Americans

Personalized Medicine

Volumn 4, Issue 2, 2007, Pages 157-169

  Limdi, Nita A ^a   Goldstein, J A ^b   Blaisdell, J A ^b   Beasley, T M ^b   Rivers, C A ^c   Acton, R T ^b  

^a The University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

African American; CYP2C9; European American; Pyrosequencing; Warfarin dose

Indexed keywords

CYTOCHROME P450 2C9; VITAMIN K GROUP; WARFARIN;

ADULT; AFRICAN AMERICAN; AGED; ALLELE; ANAMNESIS; ARTICLE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIETARY INTAKE; DOSE RESPONSE; EUROPEAN AMERICAN; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PHARMACOGENETICS; PHYSICAL ACTIVITY; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; RACE DIFFERENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THROMBOEMBOLISM; TREATMENT INDICATION; UNIVARIATE ANALYSIS;

EID: 34249823331     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.4.2.157     Document Type: Article

References (50)

1. Rendic S, Di Carlo FJ: Human cytochrome P450 enzymes: a status report summarizing their reactions. substrates, inducers, and inhibitors. Drug Metab. Rev. 29, 413-580 (1997).
2. Evans WE, Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491 (1999).
3. Nelson DR: Introductory remarks on human CYPs. Drug Metab. Rev. 34, 1-5 (2002).
4. Rettie AE. Jones JP: Clinical and toxicological relevance of CYP2C9. drug-drug interactions and pharmacogenetics. Annu. Rev. Pharmacol. Toxicol. 45, 477-494 (2005).
5. Lasker JM, Wester MR, Aramsombatdee E. Raucy JL: Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch. Biochem. Biophys. 353, 16-28 (1998).
6. Miners JO. Birkett DJ: Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol. 45, 525-538 (1998).
7. Pirmohamed M, Park BK: Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology 192, 23-32 (2003).
8. Pirmohamed M, Park BK: Genetic susceptibility to adverse drug reactions. Trends Pharmacol. Sci. 22, 298-305 (2001).
9. Xie HG, Prasad HC, Kim RB, Stein CM: CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug Deliv. Rev. 54, 1257-1270 (2002).
10. Kirchheiner J, Brockmoller J: Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther. 77, 1-16 (2005).
11. Herman D. Locatelli I, Grabnar I et al.: Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J. 5, 193-202 (2005).
12. Higashi MK, Veenstra DL. Kondo LM et al.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287, 1690-1698 (2002).
13. Margaglione M, Colaizzo D, D'Andrea G et al.: Genetic modulation of oral anticoagulation with warfarin. Thromb. Haemost. 84, 775-778 (2000).
14. Schalekamp T, Brasse BP. Roijers JF et al.: VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin. Pharmacol. Ther. 80, 13-22 (2006).
15. Schalekamp T, Brasse BP, Roijers JF et al.: VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. Clin. Pharmacol. Ther. 81, 185-193 (2007).
16. Tassies D, Freire C, Pijoan J et al.: Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica 87, 1185-1191 (2002).
17. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96, 1816-1819 (2000).
18. Veenstra DL, Blough DK, Higashi MK et al.: CYP2C9 haplotype structure in European-American warfarin patients and association with clinical outcomes. Clin. Pharmacol. Ther. 77, 353-364 (2005).
19. Havrda DE, Mai T, Chonlahan J: Enhanced antithrombotic effect of warfarin associated with low-dose alcohol consumption. Pharmacotherapy 25, 303-307 (2005).
20. McGriff-Lee NJ, Csako G, Chen JT et al.: Search for predictors of nontherapeutic INR results with warfarin therapy. Ann. Pharmacotherapy 39, 1996-2002 (2005).
21. Wittkowsky AK, Devine EB: Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin. Pharmacotherapy 24, 1311-1336 (2004).
22. Lenz TL, Lenz NJ, Faulkner MA: Potential interactions between exercise and drug therapy. Sports Med. 34, 293-306 (2004).
23. Shibata Y, Hashimoto H, Kurata C, Ohno R, Kazul T, Takinami M: Influence of physical activity on warfarin therapy. Thromb. Haemost. 80, 203-204 (1998).
24. Booth SL. Weihrauch JL, Ferland G: Vitamin K (phylloquinone) content of foods. J. Food Comp. Anal. 6, 109-120 (1993).
25. Allabi AC, Gala JL, Horsmans Y et al.: Functional impact of CYP2C95. CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. Clin. Pharmacol. Ther. 76(2). 113-118 (2004).
26. Blaisdell J, Jorge-Nebert LF, Coulter S et al.: Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 14, 527-537 (2004).
27. Sullivan-Klose TH, Ghanayem BI, Bell DA et al.: The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6, 341-349 (1996).
28. Guo SW, Thompson EA: Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics 48, 361-372 (1992).
29. Limdi NA, Beasley TM, Allison DB, Rivers CA, Acton RT: Racial differences in the prevalence of factor V Leiden mutation among patients on chronic warfarin therapy. Blood Cells Mol. Dis. 37, 100-106 (2006).
30. Kealey C, Chen Z, Christie J et al.: Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity. Pharmacogenomics 8, 217-225 (2007).
31. Xie HG, Kim RB, Wood AJ, Stein CM: Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol. 41, 815-850 (2001).
32. Redman AR, Dickmann LJ, Kidd RS, Goldstein JA, Ritchie DM, Hon YY: CYP2C9 genetic polymorphisms and warfarin. Clin. Appl. Thromb. Hemost. 10, 149-154 (2004).
33. Dickmann LJ, Rettie AE, Kneller MB et al.: Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol. Pharmacol. 60, 382-387 (2001).
34. Kuffner T, Whitworth W, Jairam M, McNicholl J: HLA class II and TNF genes in African-Americans from the southeastern United States: regional differences in allele frequencies. Hum. Immunol. 64, 639-647 (2003).
35. Reed TE: Caucasian genes In American Negroes. Science 165, 762-768 (1969).
36. Reitnauer PJ, Go RC, Acton RT et al.: Evidence for genetic admixture as a determinant in the occurrence of insulin-dependent diabetes mellitus in U.S. blacks. Diabetes 31, 532-537 (1982).
37. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA: Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 11, 803-808 (2001).
38. Tai G, Farin F, Rieder MJ et al.: In vitro and in vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose. Pharmacogenet. Genomics 15, 475-481 (2005).
39. Gotoh O: Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J. Biol. Chem. 267, 83-90 (1992).
40. Shintani M, Ieiri I, Inoue K et al.: Genetic polymorphisms and functional characterization of the 5′-flanking region of the human CYP2C9 gene: in vitro and in vivo studies. Clin. Pharmacol. Ther. 70, 175-182 (2001).
41. Imai J, Ieiri I, Mamiya K et al.: Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics 10, 85-89 (2000).
42. Williams PA, Cosme J, Ward A, Angove HC, Matak Vinkovic D, Jhoti H: Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 424, 464-468 (2003).
43. Seifert A, Tatzel S, Schmid RD, Pleiss J: Multiple molecular dynamics simulations of human p450 monooxygenase CYP2C9: the molecular basis of substrate binding and regioselectivity toward warfarin. Proteins 64, 147-155 (2006).
44. Wadelius M, Chen LY, Eriksson N et al.: Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet. 121, 23-34 (2007).
45. Wadelius M, Sorlin K, Wallerman O et al.: Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J. 4, 40-48 (2004).
46. Kimmel SE, Christie J, Kealey C et al.: Apolipoprotein E genotype and warfarin dosing among Caucasians and African-Americans. Pharmacogenomics J. (2007).
47. Bodin L, Verstuyft C, Tregouet DA et al.: Cytochrome P450 2C9 ( CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106, 135-140 (2005).
48. Sconce EA, Khan TI, Wynne HA et al.: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106, 2329-2333 (2005).
49. Schelleman H, Chen Z, Kealey C et al.: Warfarin response and vitamin K epoxide reductase complex 1 in African-Americans and Caucasians. Clin. Pharmacol. Ther. (2007) (Epub ahead of print).
50. Thom T, Haase N, Rosamond W et al.: Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113, E85-E151 (2006).